Goldman Sachs analyst Corinne Johnson initiated coverage of Syndax (SNDX) with a Buy rating and $18 price target implying 100% upside potential. The firm’s positive view is based on the near-term and peak revenue opportunity for Revuforj, Syndax’s wholly-owned lead drug currently approved for the treatment of relapsed/refractory acute myeloid leukemia patients. It estimates peak sales at $1.1B before considering potential use in the frontline setting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Promising Growth Potential for Syndax Pharmaceuticals Driven by Revuforj and Strategic Partnerships
- William Meury Resigns from Syndax Pharmaceuticals Board
- Syndax granted priority review for Revuforj sNDA by FDA
- Promising Potential of Syndax Pharmaceuticals’ Revuforj Drives Buy Rating
- Syndax reports publication of revumenib data from BEAT AML trial